S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
66,000% upside on tiny biotech? (Ad)
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
66,000% upside on tiny biotech? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
66,000% upside on tiny biotech? (Ad)
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
66,000% upside on tiny biotech? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
66,000% upside on tiny biotech? (Ad)
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
66,000% upside on tiny biotech? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Slow start to New York's legal pot market leaves farmers holding the bag
66,000% upside on tiny biotech? (Ad)
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
66,000% upside on tiny biotech? (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price & News

$36.05
+1.38 (+3.98%)
(As of 06/2/2023 ET)
Compare
Today's Range
$34.56
$36.07
50-Day Range
$24.26
$41.38
52-Week Range
$23.09
$48.48
Volume
942,438 shs
Average Volume
881,385 shs
Market Capitalization
$3.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.54

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
61.1% Upside
$58.08 Price Target
Short Interest
Bearish
5.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
0.72mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$2.42 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.38) to ($2.48) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

274th out of 983 stocks

Pharmaceutical Preparations Industry

121st out of 486 stocks


ARWR stock logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Stock News Headlines

Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
Where Arrowhead Pharma Stands With Analysts
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 5.2%
See More Headlines

ARWR Price History

ARWR Company Calendar

Last Earnings
5/02/2023
Today
6/04/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
9/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
329
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$58.08
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+59.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
13 Analysts

Profitability

Net Income
$-176,060,000.00
Pretax Margin
-54.37%

Debt

Sales & Book Value

Annual Sales
$243.23 million
Book Value
$4.35 per share

Miscellaneous

Free Float
101,555,000
Market Cap
$3.85 billion
Optionable
Optionable
Beta
0.99

Key Executives

  • Christopher Richard AnzaloneChristopher Richard Anzalone
    President, Chief Executive Officer & Director
  • Patrick C. O'brienPatrick C. O'brien
    COO, Secretary & Chief Compliance Officer
  • Kenneth Allen MyszkowskiKenneth Allen Myszkowski
    Chief Financial Officer
  • Javier San Martin
    Chief Medical Officer
  • Peter Carignan
    Vice President-Clinical Operations













ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2023?

13 Wall Street analysts have issued 12-month price objectives for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $27.00 to $90.00. On average, they anticipate the company's stock price to reach $58.08 in the next year. This suggests a possible upside of 61.1% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2023?

Arrowhead Pharmaceuticals' stock was trading at $40.56 at the start of the year. Since then, ARWR stock has decreased by 11.1% and is now trading at $36.05.
View the best growth stocks for 2023 here
.

Are investors shorting Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 5,230,000 shares, an increase of 8.1% from the April 30th total of 4,840,000 shares. Based on an average daily trading volume, of 1,150,000 shares, the days-to-cover ratio is currently 4.5 days. Currently, 5.1% of the shares of the company are short sold.
View Arrowhead Pharmaceuticals' Short Interest
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its earnings results on Tuesday, May, 2nd. The biotechnology company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $1.10. The biotechnology company had revenue of $146.27 million for the quarter, compared to analysts' expectations of $45.48 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 33.49% and a negative net margin of 53.83%. The business's revenue for the quarter was down 3.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.41 EPS.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.89%), State Street Corp (5.52%), JPMorgan Chase & Co. (2.72%), Geode Capital Management LLC (1.94%), Credit Suisse AG (1.30%) and FMR LLC (1.28%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Patrick O'brien and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $36.05.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $3.85 billion and generates $243.23 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

The company employs 329 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -